Tirofiban Hydrochloride(tye row fye’ ban)
Aggrastat
PREGNANCY CATEGORY B
Drug Classes
Antiplatelet
Glycoprotein IIb/IIIa inhibitor
Therapeutic Actions
Inhibits platelet aggregation by binding to the platelet receptor glycoprotein IIb/IIIa, which prevents the binding of fibrinogen and other adhesive ligands to the platelet.
Indications
Treatment of acute coronary syndrome in combination with heparin
Prevention of cardiac ischemic complications in patients undergoing elective, emergency, or urgent percutaneous coronary intervention
Contraindications and Cautions
Contraindicated with allergy to any component of this product, bleeding diathesis, hemorrhagic stroke, active or abnormal bleeding or stroke within 30 days, uncontrolled or severe hypertension, major surgery within 4 wk, low platelet count, aortic aneurysm, aortic dissection, acute pericarditis, history of intracranial hemorrhage, intracranial neoplasm, aneurysm.
Use cautiously with pregnancy, lactation, renal insufficiency, the elderly, platelet count less than 150,000/mm3, dialysis.
Available Forms
Injection—50 mcg/mL
Dosages
Adults
0.4 mcg/kg/min IV infusion over 30 min, then continue at rate of 0.1 mcg/kg/min IV.
Pediatric patients
Not recommended.
Patients with renal impairment
Use one-half the recommended adult dosage and monitor patient closely if CrCl is less than 30 mL/min.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
